First in Human, Single Ascending Dose Study

• Status: Completed
• Trial end date: 2022-08-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to evaluate the safety and tolerability of single ascending oral doses of INV-101 in healthy adult subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Innovo Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Healthy, adult, male or female (of non-childbearing potential only), 19-55 years of age, inclusive, at the screening visit.

• Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit.

Exclusion Criteria:

• Mentally or legally incapacitated or had significant emotional problems at the time of the screening visit or expected during the conduct of the study.

• History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.